Sign up for our daily briefing
Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Denver news in your inbox
Catch up on the most important stories affecting your hometown with Axios Denver
Des Moines news in your inbox
Catch up on the most important stories affecting your hometown with Axios Des Moines
Minneapolis-St. Paul news in your inbox
Catch up on the most important stories affecting your hometown with Axios Twin Cities
Tampa Bay news in your inbox
Catch up on the most important stories affecting your hometown with Axios Tampa Bay
Charlotte news in your inbox
Catch up on the most important stories affecting your hometown with Axios Charlotte
Kevzara was tested on critically ill coronavirus patients. Photo: Robert Nickelsberg/Getty Images
Regeneron Pharmaceuticals and Sanofi have shut down the late-stage clinical trial that was testing whether their existing arthritis drug, Kevzara, could improve the condition of COVID-19 patients who were on ventilators.
The bottom line: Kevzara fared no better than a placebo, as it failed to help COVID-19 patients recover or prevent death. Remdesivir remains as the only treatment that has shown any kind of benefit for sick coronavirus patients, although dexamethasone appears to hold the most promise.